HER2 Support Group Forums - View Single Post - Promising treatment option and improved survival rates for patients with ovarian, bre

News · 11-11-2014, 02:10 AM

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new...

More...

11-11-2014, 02:10 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,104	Promising treatment option and improved survival rates for patients with ovarian, bre Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new... More...